New Delhi: The Drug Controller General of India (DCGI) has approved the use of oral antiviral drug Favipiravir for clinical trials in the treatment of mild to moderate cases of COVID-19.
The Mumbai-based Glenmark Pharmaceuticals Ltd, which markets the drug in India, informed this on Friday.
“This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of the accelerated approval process, considering the emergency situation and unmet medical need of the Covid-19 outbreak,” Hindustan Times reported quoting a statement from Glenmark.
This approval comes as a glint of hope as the nation struggles to flatten the consistent upward curve of COVID-19 cases. The focus is on repurposed drugs and with 10 in the basket so far, the results are likely to be clear in the next two or three months.
Besides Favipiravir, DGCI has already approved ACQH, Umifenovir (Arbidol) and Mycobacterium W (anti-leprosy drug) for clinical trials in treating coronavirus patients.
Also Read: Centre Plans ‘Compassionate Use’ Of Under Trial Drugs For Severe COVID Cases
Also Read: WHO Hails Dexamethasone Trial Results Of COVID-19
Mumbai: Recently, some morphed pictures of actress Shweta Tiwari and her good friend Vishal Aditya…
Phulbani: Two tribal men were sentenced to life imprisonment by a special court in Odisha's…
New Delhi: It’s been just over two months since Atishi took oath as Delhi’s chief…
Bhubaneswar: In a moment of pride for AIIMS Bhubaneswar, Dr Manita Tamang, a final-year Senior…
Imphal: In view of the surge in violence in troubled Manipur, the Central government will send…
New Delhi/Bhubaneswar: The 7th edition of Odisha Parba got off to a colourful start in…
Mumbai: Celebrity couple Naga Chaitanya and Sobhita Dhulipala are set to walk down the aisle…
Mumbai: Ticket sales for the highly-anticipated Coldplay Infinity concerts across Indian cities kickstarted at 12…